title: Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
abstract: BACKGROUND
  Agomelatine was efficacious in reducing symptoms in a short-term placebo-controlled trial in generalized anxiety disorder (GAD) and in preventing relapse in a longer term placebo-controlled study. An additional short-term placebo-controlled study is required by regulatory agencies to confirm the efficacy of agomelatine in GAD.
  
  
  METHODS
  This 12-week, placebo-controlled, double-blind, randomized, parallel group, international, multicenter study was designed to confirm the efficacy of agomelatine 25-50 mg/d in the treatment of patients with a primary DSM-IV-TR diagnosis of GAD. The primary outcome measure was the Hamilton Anxiety Rating Scale (HARS) total score. Assay sensitivity was evaluated by including an escitalopram (10-20 mg/d) group.
  
  
  METHODS
  The study was undertaken in 45 clinical centers in Argentina, Czech Republic, Finland, South Korea, Poland, Russia, and Slovakia from April 2010 to July 2011.
  
  
  RESULTS
  One hundred thirty-nine outpatients were included in the agomelatine group, 131 in the placebo group, and 142 in the escitalopram group. Agomelatine significantly reduced mean (SD) HARS total score (agomelatine-placebo difference: 4.71 [1.03], P <.0001) and had significant effects on secondary outcome measures, including psychic and somatic HARS subscales, response rate (estimate [standard error]) (agomelatine-placebo difference: 27.4% [5.9%], P< .0001), remission on the HARS (agomelatine-placebo difference: 16.8% [5.4%], P = .002), Clinical Global Impressions-Severity of Illness scale (CGI-S) (P < .001), functional impairment (P < .0001), and sleep quality (P < .001). Findings were confirmed in the subset of more severely ill patients (HARS total score ≥ 25 with or without CGI-S ≥ 5 at baseline). Agomelatine was well tolerated by patients, with no more adverse events than placebo. Escitalopram was similarly efficacious but was accompanied by a higher incidence of adverse events compared to placebo.
  
  
  CONCLUSIONS
  In clinical practice, agomelatine has at least similar efficacy to that of escitalopram for the short-term treatment of GAD and is well tolerated.
  
  
  BACKGROUND
  Controlled-Trials.com identifier: ISRCTN03554974.
authors.affiliation: University of Cape Town Department of Psychiatry, Groote Schuur Hospital, J-Block, Anzio Rd, Observatory, Cape Town 7925, South Africa dan.stein@uct.ac.za.
authors.forename: Dan J
authors.initials: DJ
authors.lastname: Stein
authors.forename: Antti
authors.initials: A
authors.lastname: Ahokas
authors.forename: Miguel S
authors.initials: MS
authors.lastname: Márquez
authors.forename: Cyril
authors.initials: C
authors.lastname: Höschl
authors.forename: Kang Seob
authors.initials: KS
authors.lastname: Oh
authors.forename: Marek
authors.initials: M
authors.lastname: Jarema
authors.forename: Alla S
authors.initials: AS
authors.lastname: Avedisova
authors.forename: Cristina
authors.initials: C
authors.lastname: Albarran
authors.forename: Valérie
authors.initials: V
authors.lastname: Olivier
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D015283:Citalopram / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D055815:Young Adult; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D014151:Anti-Anxiety Agents; D015283:Citalopram; C084711:agomelatine; D009281:Naphthalenes